The coformulation of pembrolizumab/vibostolimab is currently being evaluated in the phase III clinical trial KEYVIBE (NCT04738487) in PD-L1 positive metastatic NSCLC as first-line treatment compared to pembrolizumab alone [171]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.